Celluris
Model RfuCAR - The Celluris’ Novel Solution
FromCelluris
The Celluris’ novel solution, named RfuCAR, was engineering in order to respond some challenges addressed by clinical trials around the world. RfuCAR is a bispecific in tandem receptor CAR, that is composed by an antigen binding domain and another domain that binds to an extracellular molecule from tumoral microenvironment.
Most popular related searches
tumor microenvironment
antigen binding
cytokine release
T-cell
clinical trial
in vivo tests
in vivo testing
in vivo test
in vivo model
cytokine
Therefore, our CAR-T solution can:
- Modulate the tumoral microenvironment by trapping an extracellular molecule, in order to reduce inhibitory signaling and to improve the CAR anti-tumoral function;
- This modulation is able to minimize the effects of CRS – Cytokine Release Syndrome and neurotoxicity, very common in patients treated with CAR-T therapy;
- Additionally, such mechanism is able to be switched-off by the administration of both receptor epitope peptides, constituting a regulatory safety switch;
- Ex vivo expansion protocols used intend to obtain a high grade purity and viability product, besides to stimulate T cells phenotype specific that increase the cytotoxicity and proliferation in vivo;
- In vitro and In vivo tests and models are being carried out to corroborate the advantages of our solution applications.
